Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer.
Weinerman
B
B
St. Boniface Hospital Department of Medicine, Manitoba Cancer Treatment & Research Foundation, Kingston, ON, Canada.
Eisenhauer
E
E
Stewart
D
D
Mertens
W
W
Tannock
I
I
Venner
P
P
Spaulding
R
R
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013453:Sulfonylurea Compounds; C058179:sulofenur